Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 1;151(7):1109-1119.
doi: 10.1002/ijc.34058. Epub 2022 May 17.

Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer

Affiliations

Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer

Rachel B Forster et al. Int J Cancer. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Int J Cancer. 2023 Sep 15;153(6):E3. doi: 10.1002/ijc.34613. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37264669 Free PMC article. No abstract available.

Abstract

Studies have suggested that prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT) are at increased risk of developing or exacerbating cardiovascular disease (CVD). We aimed to explore the association between ADT for PCa and subsequent CVD and all-cause mortality in this nationwide, longitudinal study. We also evaluated the role of cardiovascular risk and ADT duration to determine effect modification. Norwegian registry data were used to identify patients with PCa from 2008-18 and who received primary ADT in the first year after diagnosis. The associations between ADT and composite cardiovascular events, and the individual components of myocardial infarction, stroke and heart failure, in addition to atrial fibrillation and all-cause mortality, were explored using time-varying Cox regression models. We included 30 923 PCa patients, of whom 8449 (27%) received primary ADT. Mean follow-up was 2.9 and 3.8 years for CVD events and mortality, respectively. We found an association between ADT and composite CVD (adjusted HR 1.13: 95% CI 1.05-1.21), myocardial infarction (1.18: 1.05-1.32), stroke (1.21: 1.06-1.38), heart failure (1.23: 1.13-1.35) and all-cause mortality (1.49: 1.39-1.61). These associations persisted in those with low and moderate CVD risk and ADT longer than 7 months. A relationship between ADT and composite CVD and all-cause mortality was observed, especially in those with moderate CVD risk and longer treatment duration. Future studies with more detailed cancer data are needed to verify the clinical relevance of these results, especially when considering all-cause mortality within the context of treatment guidelines and benefits of ADT.

Keywords: androgen deprivation therapy; cardiovascular disease; epidemiology; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interests.

Figures

FIGURE 1
FIGURE 1
Selection of the study population (including cancer‐free males living in Norway January 1st, 2008) [Color figure can be viewed at wileyonlinelibrary.com]

Similar articles

Cited by

References

    1. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami H‐O. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst. 2012;104:1335‐1342. - PMC - PubMed
    1. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population‐based PCBaSe Sweden. J Clin Oncol. 2010;28:3448‐3456. - PubMed
    1. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin J‐F, Suissa S. Androgen‐deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60:1244‐1250. - PubMed
    1. Jespersen CG, Nørgaard M, Borre M. Androgen‐deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a Nationwide Danish population‐based cohort study. Eur Urol. 2014;65:704‐709. - PubMed
    1. Zhao J, Zhu S, Sun L, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta‐analysis of population‐based observational studies. PLoS ONE. 2014;9:e107516. - PMC - PubMed

Publication types

MeSH terms